Understanding how a specific protein modification affects cell function and disease.
Arginyl-tRNA beyond translation: mechanism and regulation of protein arginylation
['FUNDING_OTHER'] · CASE WESTERN RESERVE UNIVERSITY · NIH-10895440
This study is looking at how a special process called arginylation, which helps control how proteins break down in our cells, works and how it might be linked to diseases like Parkinson's and some cancers, with the hope that this knowledge can lead to new treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CASE WESTERN RESERVE UNIVERSITY (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10895440 on ClinicalTrials.gov |
What this research studies
This research investigates the role of arginyl-tRNA in a unique protein modification called arginylation, which is crucial for regulating protein turnover in cells. The study aims to uncover the mechanisms by which a specific enzyme, ATE1, facilitates this process and how it impacts various cellular functions, including responses to stress and aging. By using advanced techniques in structural and biochemical analysis, the research will explore how arginylation affects proteins involved in diseases like Parkinson's and certain cancers. Patients may benefit from insights gained into how these processes can be targeted for therapeutic interventions.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals diagnosed with Parkinson's disease or specific types of cancers like metastatic prostate, liver, or skin cancers.
Not a fit: Patients with conditions unrelated to protein arginylation or those not experiencing the diseases targeted by this research may not receive any benefit.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for diseases associated with protein arginylation, such as certain cancers and neurodegenerative disorders.
How similar studies have performed: While the specific mechanisms of ATE1-mediated arginylation are not fully understood, related research has shown promise in understanding protein modifications and their implications in various diseases.
Where this research is happening
CLEVELAND, UNITED STATES
- CASE WESTERN RESERVE UNIVERSITY — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, YI — CASE WESTERN RESERVE UNIVERSITY
- Study coordinator: ZHANG, YI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers